Kura Oncology Inc. has received full approval from the U.S. Food and Drug Administration for KOMZIFTI™ (ziftomenib), an oral menin inhibitor, for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. This approval was supported by data from the KOMET-001 clinical trial and marks KOMZIFTI as the first and only once-daily FDA-approved menin inhibitor for this indication. The therapy has also been added to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology as a Category 2A recommended treatment option.